Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Pre-Transplantation ST2 Levels and Non-Relapse Mortality after Myeloablative Allogeneic Hematopoietic Cell Transplantation

Lars Klingen Gjærde, MD, Sisse Rye Ostrowski, MD PhD DMSc, Ass Prof, Niels Smedegaard Andersen, MD PhD DMSc, Lone Smidstrup Friis, MD PhD, Brian Kornblit, MD PhD, Søren Lykke Petersen, MD DMSc, Ida Schjødt, MD PhD, Henrik Sengeløv, MD DMSc, Prof

Blood (2020) 136 (Supplement 1): 30–31.

https://doi.org/10.1182/blood-2020-133876

Published: 2020

Journal Articles

Sirolimus with CSP and MMF as GVHD prophylaxis for allogeneic transplantation with HLA antigen–mismatched donors

Brian Kornblit, Barry E. Storer, Niels S. Andersen, Michael B. Maris, Thomas R. Chauncey, Effie W. Petersdorf, Ann E. Woolfrey, Mary E. D. Flowers, Rainer Storb, David G. Maloney, Brenda M. Sandmaier

Blood (2020) 136 (13): 1499–1506.

https://doi.org/10.1182/blood.2020005338

Published: 2020

Includes: Supplemental data

Journal Articles

Sirolimus Combined with Cyclosporine (CSP) and Mycophenolate Mofetil (MMF) As Graft-Vs-Host Disease (GVHD) Prophylaxis after Nonmyeloablative (NMA) Hematopoietic Cell Transplantation (HCT) Using HLA Class I or Class II Antigen Mismatched Donors: Results from a Phase II Multi-Center Trial

Brian Kornblit, MD PhD, Barry Storer, Michael B. Maris, MD, Niels Smedegaard Andersen, MD PhD, Thomas R. Chauncey, MD PhD, Effie W. Petersdorf, MD, Ann Woolfrey, MD, David G. Maloney, MD PhD, Rainer Storb, MD, Brenda M Sandmaier, MD

Blood (2019) 134 (Supplement_1): 369.

https://doi.org/10.1182/blood-2019-123196

Published: 2019

Journal Articles

The Prognostic Value of YKL-40 in Allogeneic Hematopoietic Cell Transplantation

Brian Kornblit, MD PhD, Tao Wang, PhD, Stephanie J. Lee, MD MPH, Stephen R. Spellman, MBS, Xiaochun Zhu, MS, Katharina Fleischhauer, MD, Carlheinz Müller, MD PhD, Michael R. Verneris, MD, Julia S. Johansen, MD DMSci, Lars Vindelov, MD DMSci, Peter Garred, MD DMSci

Blood (2014) 124 (21): 1176.

https://doi.org/10.1182/blood.V124.21.1176.1176

Published: 2014

Journal Articles

Durable donor engraftment after radioimmunotherapy using α-emitter astatine-211–labeled anti-CD45 antibody for conditioning in allogeneic hematopoietic cell transplantation

Yun Chen, Brian Kornblit, Donald K. Hamlin, George E. Sale, Erlinda B. Santos, D. Scott Wilbur, Barry E. Storer, Rainer Storb, Brenda M. Sandmaier

Blood (2012) 119 (5): 1130–1138.

https://doi.org/10.1182/blood-2011-09-380436

Published: 2012

Journal Articles

Peripheral Blood Stem Cell Mobilization with Single Agent Plerixafor Induces FoxP3 Expression in Donor T Cells and Enables Durable Long Term Hematopoietic Engraftment Across Mismatched Major Histocompatibility Complex Barriers

Brian Kornblit, MD, PhD, Billanna Hwang, Barry Storer, PhD, Monica S Thakar, MD, Erlinda B Santos, Richard A. Nash, MD, Brenda M. Sandmaier, MD

Blood (2011) 118 (21): 1891.

https://doi.org/10.1182/blood.V118.21.1891.1891

Published: 2011

Journal Articles

Association of HMGB1 Polymorphisms with Outcome After Allogeneic Hematopoietic Cell Transplantation.

Brian Kornblit, MD, Tania Nicole Masmas, MD, Søren Lykke Petersen, Hans O Madsen, Carsten Heilmann, Lone Schejbel, Henrik Sengeloev, Klaus Müller, Peter Garred, Lars Vindelov, MD

Blood (2009) 114 (22): 2260.

https://doi.org/10.1182/blood.V114.22.2260.2260

Published: 2009

Journal Articles

Genetic Variation in AKAP13 Is Associated with Increased Risk of Relapse after Allogeneic Hematopoietic Cell Transplantation Following Non-Myeloablative Conditioning.

Brian Kornblit, MD, Tania Masmas, Hans O Madsen, Mette V Larsen, Anette Stryhn, Søren Buus, Peter Garred, Lars Vindelov

Blood (2008) 112 (11): 3257.

https://doi.org/10.1182/blood.V112.11.3257.3257

Published: 2008

Journal Articles

The PTPN22 1858C/T Polymorphism Is Associated with the Development of Grade 3 to 4 Acute Graft-Versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation Following Nonmyeloablative Conditioning.

Brian Kornblit, MD, Tania Masmas, MD, Soren L. Petersen, MD, Hans O. Madsen, MSc, Peter Garred, MD, Lars Vindelov, MD

Blood (2007) 110 (11): 1969.

https://doi.org/10.1182/blood.V110.11.1969.1969

Published: 2007

NARROW

Pre-Transplantation ST2 Levels and Non-Relapse Mortality after Myeloablative Allogeneic Hematopoietic Cell Transplantation

Sirolimus with CSP and MMF as GVHD prophylaxis for allogeneic transplantation with HLA antigen–mismatched donors

Sirolimus Combined with Cyclosporine (CSP) and Mycophenolate Mofetil (MMF) As Graft-Vs-Host Disease (GVHD) Prophylaxis after Nonmyeloablative (NMA) Hematopoietic Cell Transplantation (HCT) Using HLA Class I or Class II Antigen Mismatched Donors: Results from a Phase II Multi-Center Trial

The Prognostic Value of YKL-40 in Allogeneic Hematopoietic Cell Transplantation

Durable donor engraftment after radioimmunotherapy using α-emitter astatine-211–labeled anti-CD45 antibody for conditioning in allogeneic hematopoietic cell transplantation

Peripheral Blood Stem Cell Mobilization with Single Agent Plerixafor Induces FoxP3 Expression in Donor T Cells and Enables Durable Long Term Hematopoietic Engraftment Across Mismatched Major Histocompatibility Complex Barriers

Association of HMGB1 Polymorphisms with Outcome After Allogeneic Hematopoietic Cell Transplantation.

Genetic Variation in AKAP13 Is Associated with Increased Risk of Relapse after Allogeneic Hematopoietic Cell Transplantation Following Non-Myeloablative Conditioning.

The PTPN22 1858C/T Polymorphism Is Associated with the Development of Grade 3 to 4 Acute Graft-Versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation Following Nonmyeloablative Conditioning.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only